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Background: Neuroinflammation is a hallmark that leads to selective neuronal loss and/or dysfunction in
neurodegenerative disorders. Microglia-derived lysosomal cathepsins are increasingly recognized as important
inflammatory mediators to trigger signaling pathways that aggravate neuroinflammation. However, cathepsin H
(Cat H), a cysteine protease, has been far less studied in neuroinflammation, compared to cathepsins B, D, L, and
S. The expression patterns and functional roles of Cat H in the brain in neuroinflammation remain unknown.
Methods: C57BL/6J mice were intraperitoneally injected with either 0.9% saline or lipopolysaccharide (LPS, 5 mg/kg).
Immunohistochemistry (IHC) and in situ hybridization (ISH) were used to analyze expression and localization of Cat H in
the brain. Nitrite assay was used to examine microglial activation in vitro; ELISA was used to determine the release of
Cat H and proinflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ). Cat H activity was analyzed by cellular Cat H assay kit.
Flow cytometry and in situ cell death detection were used to investigate neuronal death. Data were evaluated for
statistical significance with one-way ANOVA and t test.
Results: Cat H mRNA was only present in perivascular microglia and non-parenchymal sites under normal
conditions. After LPS injection, Cat H mRNA expression in activated microglia in different brain regions was
increased. Twenty-four hours after LPS injection, Cat H mRNA expression was maximal in SNr; 72 h later, it peaked
in cerebral cortex and hippocampus then decreased and maintained at a low level. The expression of Cat H
protein exhibited the similar alterations after LPS injection. In vitro, inflammatory stimulation (LPS, TNF-α, IL-1β,
IL-6, and IFN-γ) increased the release and activity of Cat H in microglia. Conversely, addition of Cat H to microglia
promoted the production and release of NO, IL-1β, and IFN-γ which could be prevented by neutralizing antibody.
Further, addition of Cat H to Neuro2a cells induced neuronal death.
Conclusions: Taken together, these data indicate that the up-regulated microglial Cat H expression, release, and
activity in the brain lead to neuronal death in neuroinflammation. The functional link of Cat H with microglial
activation might contribute to the initiation and maintenance of microglia-driven chronic neuroinflammation.
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The central nervous system (CNS) is regarded as an
immune-privileged site because of the blood-brain barrier
(BBB) and an immunosuppressive environment. However,
in many neurological conditions, there is a loss of immune
privilege, for instance, in a variety of neurodegenerative
diseases, including Alzheimer’s disease, Parkinson’s dis-
ease, Huntington’s disease, and amyotrophic lateral scler-
osis [1-4]. In these diseases, certain microenvironmental
factors, such as glia overactivation, cytokines overproduc-
tion, BBB permeability increase, and peripheral immune
cells infiltration, are recognized to be one of prominent
pathological features. These characteristic pathological
changes are generally described as neuroinflammation,
which are thought to contribute to neuronal injuries and
aggravation of neurodegenerative diseases [5-7]. To date,
much attention has been given to microglia, a pivotal cel-
lular player in neuroinflammation [8-12].
Microglia are the immune cells resident in the CNS,
serving the role of tissue maintenance and immune sur-
veillance of the brain [13,14]. Under inflammatory con-
ditions, microglia are over-activated and secrete various
inflammatory mediators including nitric oxide (NO), re-
active oxygen species (ROS), and proinflammatory cyto-
kines such as TNF-α and IL-1β [15-17].
There is increasing evidence that activated microglia
also induce the synthesis and secretion of lysosomal ca-
thepsins [18-22], in particular at the early stage of inflam-
mation, to trigger signaling pathways in a pathological
cascade that aggravate neuroinflammation. Cathepsins, a
large group of lysosomal proteases, are subdivided into
three subgroups according to the amino acids of their ac-
tive sites that confer catalytic activity: cysteine (cathepsins
B, C, F, H, K, L, N, O, S, T, U, W, and X), aspartyl (cathep-
sins D and E), and serine cathepsins (cathepsins A and G)
[23]. These proteases play a central role in a number of
important cellular processes such as degradation of intra-
cellular proteins, extracellular matrix remodeling, and
apoptosis. To date, in neuroinflammation, most of the re-
search has focused on cathepsins B, D, L, and S, which ap-
pear to be most active in inflammatory response and play
a key role in the neurotoxic effects [24-28]. In contrast, ca-
thepsin H (Cat H) has been far less studied in this aspect.
Cat H is a cysteine protease involved in lysosomal pro-
tein degradation [29-31]. Cat H is synthesized as an enzy-
matically inactive proenzyme (procathepsin H, 41 kDa) in
endoplasmic reticulum and then proteolytically processed
to an active single-chain, mature form (28 kDa) within the
endosomes/lysosomes. Unlike other members of the fam-
ily, Cat H is unique in that it is both an exopeptidase (ami-
nopeptidase) and an endopeptidase with a pH optimum of
about 6.5 to 6.8 [32-35]. Cat H acts as an important con-
tributor to inflammatory pathologies and tumor metasta-
sis depending largely on its aminopeptidase activity whichis determined by residual octapeptide EPQNCSAT of the
propeptide termed mini-chain that limits the access of sub-
strates to the catalytic center [36-39]. It has been implied
that Cat H provokes acute inflammation characterized by
the accumulation of polymorphonuclear leukocytes (PMN)
when injected intracutaneously into newborn rats [40].
Additionally, Cat H level was elevated in inflammatory
acute lung injuries [41,42], pancreatitis [43], inflammatory
myopathy [44], and atherogenesis [45]. Moreover, Cat H
level has a significant positive correlation with the severity
of inflammation in these diseases.
Despite the extensive literature describing Cat H and
peripheral inflammatory diseases, there is limited insight
into the CNS inflammatory processes that Cat H may
regulate. There are several findings that Cat H immunore-
activity in the hippocampus is increased in animal model
of cerebral ischemia, and Cat H activity increases in af-
fected brain areas in Huntington’s disease [29]. These
findings imply a potential role of Cat H in the neuroin-
flammatory pathogenesis of neurological diseases.
In the present study, we set out to gain further insight
into the functional roles of Cat H in neuroinflammation
by investigating the temporal and spatial expression pat-
terns and cellular localization of Cat H in the brain in
the lipopolysaccharide (LPS)-induced neuroinflamma-
tion, as well as impact of Cat H on microglial activation
and of neuronal survival.
Materials and methods
Animals
Eight-week-old C57BL/6J mice weighing 25 to 30 g were
used in the experiments. Animals were housed in groups
of five per cage in a 22°C ± 2°C and 45% ~ 65% relative hu-
midity environment under a normal light cycle room (12-
h light/12-h dark; 8:00 a.m. light on ~ 8:00 p.m. light off).
All animals had free access to food and water. All proce-
dures were in accordance with the Dalian Medical Univer-
sity Guidelines for the proper care and use of Laboratory
Animals and were approved by the Laboratory Animal
Care and Use Committee of Dalian Medical University.
LPS treatment
Lipopolysaccharide (LPS, Escherichia coli, serotype O55:
B5, Sigma-Aldrich, St. Louis, MO, USA) was used to in-
duce an inflammatory response. LPS was injected intra-
peritoneally at a dose of 5 mg/kg dissolved in sterile,
endotoxin-free 0.9% saline vehicle. Control injections were
equivolume vehicle. The dosage of LPS was based on a
previous study of LPS-induced neurotoxicity [46,47].
Tissue preparation
At the time points of 6 h, 24 h, 72 h, 7 days, and 10 days
after LPS injection, mice were anesthetized with diethy-
lether and perfused with 4% paraformaldehyde solution.
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protected in 20% sucrose solution and embedded in OCT
compound (McCormick Scientific, St. Louis MO, USA);
and serial 18 μm sagittal sections were made with a cryo-
stat (Leica CM 3050S, Solms, Germany) and used for the
immunohistochemical (IHC) and in situ hybridization
(ISH) studies.
For ELISA, mice were perfused with ice-cold PBS, and
then the brains were removed and homogenized on ice.
The homogenates were centrifugated at 12,000 g for 5
min at 4°C. The supernate was stored at −80°C.
In situ hybridization
ISH was performed as described previously [48]. After
hybridization of Cat H (NM_007801, 35 to 1,200 bp)
cRNA probe, samples were incubated overnight with al-
kaline phosphatase-conjugated anti-digoxigenin (DIG)
antibody (Roche, Basel, Switzerland) at 4°C. Color devel-
opment was achieved by incubation with NBT/BCIP for
16 h at room temperature. Some sections were counter-
stained with Nuclear Fast Red for observation and ana-
lysis; others were processed for Iba-1, GFAP, and NeuN
IHC staining after ISH, respectively. Images were cap-
tured using the Nikon digital camera system (DS-Fi1) in
combination with microscopy (Nikon Eclipse 80i, Nikon,
Tokyo, Japan). The number of cells expressing Cat H
mRNA was counted with ImageJ 1.41 (National Insti-
tutes of Health, Bethesda, Maryland). Three sections
from each mouse (with five mice per condition) were
used for analysis.Immunohistochemical staining
IHC was performed as described by Ma et al. [49]. The fol-
lowing antibodies were used: mouse anti-NeuN monoclo-
nal antibody (1:1,000, Chemicon, EMD Millipore, Billerica,
MA, USA), rabbit anti-GFAP polyclonal antibody (1:1,000,
Dako, Glostrup, Denmark), rabbit anti-Iba1 polyclonal
antibody (1:500, Wako, Osaka, Japan). Secondary anti-
bodies were labeled with biotin (1:200, Vector Laboratory,
Burlingame, CA, USA). After IHC reaction, images were
captured using the Nikon digital camera system (DS-Fi1)
in combination with microscopy (Nikon Eclipse 80i).
Real-time quantitative PCR
Total RNA was extracted from the brain using TRIzol re-
agent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Reverse transcription was per-
formed using SuperScript II Reverse Transcriptase (Invi-
trogen). Real-time quantitative PCR was performed in 25
μL reaction volume using SYBR green PCR Master Mix
(Thermo Scientific, Waltham, MA, USA), as described by
the manufacturer. The primer sequences are the following:Cat H: forward: 5′ GAGCAGCAGCTGGTGGATTG 3′,
reverse: 5′ CCATGATGCCCTTGTTGTATAGGA 3′; β-
actin: forward: 5′ ATCATGTTTGAGACCTTCAACA
3′, reverse: 5′ CATCTCCTGCTCGAAGTCTA 3′. All
primers were synthesized by Takara Biotechnology Co.
Ltd. (Dalian, China). The thermal cycling conditions in-
cluded denaturation step at 95°C for 10 min, followed
by 40 cycles at 95°C for 15 s, 60°C for 30 s, and 72°C for
30 s and the final melting curve program with ramping
rate of 0.5°C/s from 55°C to 95°C. Amplification specificity
of PCR products was confirmed by melting curve analysis
and agarose gel electrophoresis. Fold regulation values
were calculated relative to the expression mean of the
group displaying the lowest expression.Cell culture
Primary microglia were harvested from primary mixed
glial cell cultures prepared from neonatal C57BL/6J mice
pups as previously reported (Fan et al., [18]). In brief, after
the meninges were carefully removed, the neonatal brain
was dissociated by pipetting. The cell suspension was
plated in 10-cm culture dish at a density of one brain per
two dishes in 10 mL DMEM (Sigma-Aldrich) containing
10% fetal bovine serum (FBS) (ICN Biomedicals, Santa
Ana, CA, USA). After 14 to 21 days in vitro, mixed glia
cultures were dissociated by trypsinization, and the cell
suspension was seeded on a petri dish and incubated for
30 min in a CO2 incubator. Adherent cells were harvested
as primary microglia. Microglia were reseeded in culture
plates. The purity of microglia was approximately 99% as
determined by CD11b (rat monoclonal IgG, clone M1/70,
Abcam, Cambridge, UK) staining.
The immortalized murine microglial cell line BV2
was a kind gift from Dr. XF Wu (Dalian Medical Uni-
versity, China) and were maintained in DMEM supple-
mented with 10% FBS, 2 mM glutamine, and 100 U/mL
penicillin/streptomycin at 37°C in 5% CO2 in a humidi-
fied atmosphere.
Prior to inflammatory treatments, primary microglia
and BV2 cells were cultured in media without FBS for
24 h at 1.0 × 105 cells/24-well plate.Cell treatment
BV2 cells were incubated for 24 h with LPS (10 ng/mL),
then the culture media were collected, centrifuged to re-
move any cellular material.
Cat H antibody (N-18, Santa Cruz Biotech, Dallas, TX,
USA) was added to the Cat H solution or microglial con-
ditioned media and incubated for 1 h to allow sufficient
time for antibody binding, then the samples were trans-
ferred to BV2 cells and incubated for 24 h. Controls were
carried out in which Cat H antibody was directly added to
BV2 cells to investigate non-specific effects.
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The production of nitric oxide (NO) in vitro was evalu-
ated indirectly by measuring nitrite concentration (Key-
GEN biotechnology, Nanjing, China). Test samples were
the media obtained from BV2 cells and primary micro-
glia following treatment with LPS (10 ng/mL), TNF-α (1
ng/mL), IL-1β (1 ng/mL), IL-6 (1 ng/mL), or IFN-γ (50
ng/mL) for 24 h, respectively. The absorbance at the
wavelength 540 nm was determined using a microplate
reader (iMark, Bio-rad, Hercules, CA, Japan).ELISA
Cat H and proinflammation factors levels in the condi-
tioned media were determined by enzyme-linked im-
munosorbent assay (ELISA).
Test samples for Cat H include brain supernate ob-
tained from LPS-injected mice, the media from primary
microglia and BV2 cells activated by LPS (10, 100, 1,000
ng/mL), IL-1β, IL-6, TNF-α (1, 10, and 100 ng/mL in
each case), IFN-γ (50,500,5,000 ng/mL) for 24 h, respect-
ively, and the media from BV2 cells treated with Cat H
(2 ng/μL) in combination with Cat H antibody. Test
samples for proinflammation factors were media from
BV2 cells exposed to recombinant active Cat H protein
(Abcam) in 0.2, 2, and 20 ng/μL, respectively.
The assay was performed according to Cat H ELISA
Kit protocols (R&D) and TNF-α, IL-1β, IL-6, and IFN-γ
ELISA Kit protocols (Peprotech, Rehovot, Israel). A mi-
croplate reader (iMark, Bio-rad, Japan) was used to
measure absorbance at 450 nm. Cat H concentration
was expressed in U/g of total protein and proinflamma-
tion factors in pg/μg of total protein.Cat H enzymatic activity assay
Cat H aminopeptidase activity was determined by deg-
radation of synthetic fluorogenic substrate L-Arg-7-
amido-4-methylcoumarin (L-Arg-AMC). Test samples
are the conditioned media obtained from primary
microglia and BV2 cells following treatments with LPS
(10 ng/mL), IL-1β, IL-6, TNF-α (10 ng/mL in each
case), and IFN-γ (500 ng/mL) for 24 h, respectively.
The procedures were performed according to Cat H assay
kit protocols (Genmed Scientifics Inc., Wilmington, DE,
USA). All samples including control groups (50 μg Cat H
protein/well in 96-well plate) were incubated with the L-
Arg-AMC at 37°C for 60 min. The release of fluorescent
AMC was measured at an excitation and emission wave-
length of 360 and 460 nm, respectively, in EnSpire Multi-
mode Plate Reader (PerkinElmer, Waltham, MA, USA).
The fluorescent signal was calibrated using known concen-
trations of AMC. Data were presented as relative folds to
untreated control.Flow cytometry
Flow cytometry was used to evaluate neuronal death fol-
lowing addition of recombinant active Cat H protein
(Abcam) in 2 and 20 ng/μL to the culture media of the
neuroblastoma cell line Neuro2a cells, respectively. After
incubation for 24 h, the cells were harvested by centrifu-
gation at 2,000 rpm for 5 min. After washing twice with
pre-cold phosphate-buffered saline (PBS, pH 7.4), cells
were resuspended in binding buffer and then stained by
Annexin V-FITC and propidium iodine (PI) for 5 to 15
min at room temperature. At last, these cells were sub-
jected to flow cytometer (Becton Dickinson, Laguna
Hills, CA, USA).
In situ cell death detection
Adherent Neuro2a cells on coverslips were incubated with
recombinant active Cat H protein (Abcam) in 20 ng/μL for
24 h. In situ cell death detection kit (TMR red, Roche) was
applied to perform TdT-mediated dUTP nick end labeling
(TUNEL) staining to evaluate neuronal apoptosis. Briefly,
the cells were fixed by 4% paraformaldehyde in PBS (pH
7.4) for 1 h at 4°C, washed in PBS, and then incubated in
permeabilization solution (0.1% Triton X-100 in 0.1% so-
dium citrate) for 2 min at 4°C. Later, the cells were incu-
bated in TUNEL reaction mixture for 1 h at 37°C in the
dark. Hoechst 33342 was used for the nuclear counter-
staining. Negative control cells were used as label solution
instead of TUNEL reaction mixture. Positive control cells
were incubated with DNase I recombinant (Takara) for 10
min at room temperature to induce DNA strand breaks,
prior to labeling procedures. The numbers of apoptotic
cells were counted using an Olympus IX70 inverted fluor-
escence microscope. Cells were scored in eight randomly
chosen fields under a magnification of × 400 per coverslip
on at least two coverslips per treatment. The percentage of
cells positive for apoptosis was calculated.
Statistical analysis
Data were expressed as mean + standard error of the mean
(SEM) from three independent experiments. All statistical
analyses were performed using the Statistical Package for
Social Sciences (Version 17.0). One-way ANOVA test was
used to detect significance of the differences among more
than two arithmetic means, followed by post hoc Scheffe
test to detect the differences between two means. Student’s
t test was used to detect the significance of differences
between two means. P < 0.05 was considered statistically
significant.
Results
Cat H expression was increased in the brain microglia in
neuroinflammation evoked by LPS systemic injection
Previous studies found that the expression and enzym-
atic activity of Cat H was up-regulated in peripheral
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roinflammation remain unknown.
In this study, we first investigated the Cat H expression
at transcriptional level in the normal brain. The ISH re-
sults showed that Cat H mRNA was absent in the brain
parenchyma, only present in cells with glial morphology,
close to the blood vessels (Figure 1A-C,J), also in non-Figure 1 Microglial Cat H expression was induced at a transcriptional
injection, Cat H mRNA expression was detected in the hippocampus (D), S
and density of Cat H mRNA positive cells were both increased in the abov
brain (A-C), present only close to the blood vessels (arrows in J). Double st
of Cat H mRNA was perivascular microglia (arrows in L). At 24 h after LPS i
brain parenchyma, in addition to perivascular microglia (arrows in K, M). Th
analyzed after LPS injection were shown in (N). The detected regions were
mean + SEM from three independent experiments. aP, fP, gP < 0.05 vs contr
Scale bar = 50 μm (A, B, D, E, G, H); 20 μm (C, F, I); 10 μm (J; K, L, M). n = 5.parenchymal sites, such as leptomeninges and the choroid
plexus in ventricles.
Next, we investigated the expression pattern of Cat H
mRNA in LPS-evoked neuroinflammation. Previously,
we reported that a single intraperitoneal injection of LPS
(5 mg/kg) on mouse-evoked apparent systemic inflam-
mation and further triggered characterized by activationlevel after LPS injection. ISH staining showed that at 6 h after LPS
Nr (E), and cerebral cortex (F). At 72 h after LPS injection, the intensity
e regions (G-I). In the control, brain Cat H mRNA was absent in the
aining (Cat H ISH following Iba-1 IHC) showed that cellular localization
njection, Cat H mRNA positive signals appeared in microglia in the
e quantification results of Cat H mRNA expression in brain regions
illustrated in sagittal section of the brain (O). Data were expressed as
ol; bP < 0.01 vs 6 h; cP < 0.05 vs 72 h; dP < 0.05 vs 24 h; eP < 0.01 vs 6 h.
Figure 2 The expression of Cat H protein was increased in the
brain after LPS injection. ELISA assay showed that brain Cat H
protein expression was increased and maximal at 72 h after LPS injection
then decreased and maintained at a low level at 10th day. Data were
expressed as mean + SEM from three independent experiments.
a,eP< 0.05 vs control; b,dP< 0.01 vs control; cP< 0.05 vs b,d. n= 5.
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inflammatory mediators (IL-1β, TNF-α, and iNOS) in
the brain [18]. Here, we first investigated Cat H expres-
sion in neuroinflammation evoked by intraperitoneal in-
jection of LPS at a low dose of 0.1 mg/kg. The ISH
staining showed no positive Cat H mRNA signals seen
in the brain at 24 h after LPS injection, and real-time
quantitative PCR results further confirmed that LPS (0.1
mg/kg, i.p.) failed to induce Cat H mRNA expression in
the brain (see Additional file 1). Thus, we next estab-
lished the mouse neuroinflammatory model with a high
dose of LPS (5 mg/kg, i.p.) to investigate the expression
patterns of Cat H in the brain.
We especially observed and analyzed brain regions
known to be affected in neurodegenerative diseases,
such as the cerebral cortex, hippocampus, and SNr. ISH
staining showed that at 6 h after LPS injection, Cat H
mRNA was expressed in the hippocampus (Figure 1D),
SNr (Figure 1E), and cerebral cortex (Figure 1F). At 24 h
after LPS injection, the intensity and density of Cat H
mRNA positive signals were both increased in a global
pattern. In SNr, the number of Cat H mRNA positive
cells was maximal at 24 h. In the cerebral cortex and
hippocampus, the highest level of Cat H mRNA expres-
sion appeared at 72 h (Figure 1G-I,N). These results in-
dicate that in inflammatory condition, the synthesis of
Cat H is markedly up-regulated at transcriptional level.
Ten days after LPS injection, Cat H mRNA expression
was decreased nearly to the level of 6 h for each region
investigated (Figure 1N).
Furtherly, we confirmed the cellular localization of Cat
H mRNA by double stainings in the following combin-
ation: NeuN (neuronal marker, IHC) following Cat H
(ISH); Iba-1 (microglia/macrophages marker, IHC) fol-
lowing Cat H (ISH); GFAP (astrocyte marker, IHC) fol-
lowing Cat H (ISH). The results showed that in the
normal brain, Cat H mRNA positive cells around vessels
were perivascular microglia/macrophages (Figure 1L),
confirming the previous studies [48,50-52]. Similarly,
after LPS injection, Cat H mRNA was predominantly
expressed in the parenchymal and perivascular micro-
glia/macrophages (Figure 1K,M), rarely in astrocytes and
neurons.
Cat H IHC staining is hard to show the spatial expres-
sion pattern of Cat H protein appropriately due to its
extracellular secretion, therefore ELISA was used in-
stead. The results showed that the level of Cat H protein
expression was strikingly increased following LPS chal-
lenge with similar alteration tendency of Cat H mRNA
(Figure 2). The results indicate that Cat H expression in
the brain is regulated at both the transcriptional and
translational levels in neuroinflammation.
Taken together, our results indicate that in normal
condition, the level of Cat H expression in the brain waslow, and LPS-evoked neuroinflammation could induce
Cat H expression in microglia.
Proinflammatory cytokines increased microglial Cat H
release and activity in vitro
IFN-γ and LPS stimulation can cause a significant in-
crease in the expression and activity of Cat H in macro-
phages [53,54]. Moreover, Cat H can be secreted via the
secretory lysosome system in inflammatory diseases
[55-57]. In our study, we wondered whether proinflam-
matory stimulation can affect Cat H secretion and activ-
ity in microglia. We examined Cat H level in culture
media of the BV2 cells or primary microglia treated with
various concentrations of LPS (10, 100, 1,000 ng/mL),
IL-1β, IL-6, TNF-α (for all 1, 10, and 100 ng/mL), and
IFN-γ (50, 500, 5,000 ng/mL).
We first determined the nitrite level in the culture media
following 24-h treatment with LPS (10 ng/mL), IL-1β, IL-6,
TNF-α (for all 1 ng/mL), or IFN-γ (50 ng/mL). There was a
significantly higher level of nitrite in the media of BV2 cells
and primary microglia after treatments, compared to un-
treated cells (see Additional file 2). This indicates that the
proinflammatory stimuli were sufficient to induce micro-
glial activation, even at the lowest concentrations.
Then, we examined the Cat H release in the culture
media of BV2 cells or primary microglia by ELISA. We
observed the low level of Cat H content in the media in
absence of proinflammatory stimuli, suggesting that there
is a basal level of Cat H production and secretion in un-
treated microglia. In contrast, the levels of Cat H were sig-
nificantly increased in the media of BV2 cells following
TNF-α, IL-1β, IL-6, and IFN-γ treatments for 24 h, re-
spectively. Among these, TNF-α and IFN-γ induced Cat H
increase in a dose-dependent manner (Figure 3B,E). Be-
sides, IL-6 treatment, to various degrees, induced Cat H
release in primary microglia (Figure 3D). However, LPS
Figure 3 Proinflammatory cytokines induced microglial Cat H release and up-regulated Cat H activity in vitro. The level of Cat H in the
media of BV2 cells and primary microglia after various inflammatory treatments for 24 h was measured by ELISA and shown in (A-E). The activity of
Cat H in the media of BV-2 cells and primary microglia after various inflammatory treatments was measured and shown in (F). Data were expressed as
mean + SEM from three independent experiments. *, #: P < 0.05; **: P < 0.01, NS: no significance in (A-E), *, #: P < 0.05 vs control in (F).
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microglia (Figure 3A). These results suggest an inducible
effect of proinflammatory cytokines on Cat H release in
microglia.
Further, we examined Cat H activity in the media of
BV2 and primary microglia following 24-hour proin-
flammatory stimulation. The results showed that stimuli
including LPS (10 ng/mL), IL-1β (10 ng/mL), IL-6 (10
ng/mL), and IFN-γ (500 ng/mL) up-regulated Cat H ac-
tivity significantly, except TNF-α (10 ng/mL), compared
to untreated cells (Figure 3F).
These results suggest that proinflammatory stimula-
tion can elevate Cat H activity, which could be associ-
ated with increased Cat H secretion.
Cat H induced microglial release of proinflammatory
cytokines which could be attenuated by neutralizing
antibody
The previous studies demonstrated that Cat H can pro-
voke acute skin inflammatory response mediated by cy-
tokines and chemokines [40].
In our study, we have found increased expression of
proinflammatory cytokines and Cat H in the brain in
neuroinflammation. Considering that activated microglia
are the main cellular sources of inflammatory mediatorsin CNS, we raised our hypothesis that Cat H could in-
duce microglial activation and further promote inflam-
matory mediator release in inflamed CNS.
To testify our hypothesis, we collected the media of
BV2 cells incubated with LPS (10 ng/mL) for 24 h, in
which the increase of Cat H content was confirmed pre-
viously. Then, we transferred the conditioned media to
BV2 cells and incubated for another 24 h. To identify
the specific effect of Cat H on BV2 cells, in other
groups, we additionally added neutralizing Cat H anti-
body (N18, 1:100 of final volume of media) to BV2 cells.
We found that the LPS-treated media promoted the
microglial TNF-α, IL-1β, IL-6, and IFN-γ release, but
addition of Cat H antibody did not change their release
from microglia (data not shown).
Considering diversity and complexity of inflammatory
mediators in the conditioned media of LPS-treated BV2
cells, we added specifically recombinant active Cat H
(0.2, 2, 20 ng/μL) to BV2 cells, respectively, to rule out
possible influences of other components in the media on
BV2 cells. We found that NO production and IL-1β and
IFN-γ release were increased dose dependently after
addition of Cat H, while TNF-α and IL-6 release was not
affected significantly(Figure 4A,B). Furthermore, we
found that the release of L-1β and IFN-γ was decreased
Figure 4 Cat H induced microglial activation and promoted release of proinflammatory cytokines in vitro. The level of nitrite in the
media of BV2 cells following various concentrations of Cat H treatments for 24 h was shown in (A). Release of cytokines in the media of BV2 cells
treated with various concentrations of Cat H was measured by ELISA and shown in (B). The effect of Cat H antibody on release of cytokines in
BV2 cells was shown in (C) (Cat H concentration is 2 ng/μL). Data were expressed as mean + SEM from three independent experiments.
a,bP < 0.01 vs control; cP < 0.05 vs a in A; a,cP < 0.05 vs control; b,dP < 0.05 vs a, c in B. **: P < 0.01 in C.
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(2 ng/μL) and neutralizing antibody (N18, 1:100 of final
volume of media) for 24 h (Figure 4C). These results
support our hypothesis that Cat H could induce micro-
glial activation and promote subsequent release of pro-
inflammatory cytokines.
Taken together, proinflammatory cytokines induced
microglial Cat H release and vice versa, which suggests
that there could be interaction between Cat H and pro-
inflammatory cytokines mediated by activated microglia.Cat H induced neuronal death in vitro
Cathepsins can cause neuronal apoptosis in neurodegen-
eration [58-63], but so far, it is unknown whether Cat H is
toxic to neurons in neuroinflammation. Next, we observed
the influence of Cat H on neuronal death by adding active
Cat H protein (2, 20 ng/μL) into the culture media of
Neuro2a for 24 h and measuring annexin-V positive cells
(A+/PI−) and double stained cells (A+/PI+) representing
apoptotic and necrotic (or late apoptotic) cells, respect-
ively, by flow cytometer.
As shown in Figure 5A-D, both percentages of apop-
tosis and necrosis in Cat H (20 ng/μL)-treated cells were
significantly higher than those of control cells, indicating
that Cat H could have a neurotoxic influence on neu-
rons resulting in neuronal death.
Further, TUNEL positive staining in in situ detection ex-
hibited apoptotic Neuro2a cells with condensed nuclear
morphology following exposure to Cat H (20 ng/μL) for
24 h (Figure 5E). A significant increase of apoptotic cells
was found following Cat H treatment, compared to un-
treated cells (Figure 5F).
These results suggest that Cat H could induce neur-
onal death through exerting neurotoxicity on neurons,which may play a crucial role in maintenance and aggra-
vation of neuroinflammatory diseases.Discussion
An inflammatory reaction in the brain is primarily char-
acterized by activation of parenchymal microglial cells.
Microglia-mediated neuroinflammation is thought to
promote brain damage in various neurodegenerative dis-
orders [8-12].
Systemic injection of LPS is often used in experimental
models of neuroinflammation, for example, Parkinson’s
disease models [46,47]. In our previous study, LPS
(5 mg/kg, i.p.) injection resulted in microglial activation
and promoted production of proinflammatory cytokines in
the mouse brain. Qin et al. reported that inflammatory re-
sponses evoked by LPS (5 mg/kg, i.p.) injection could per-
sist for several months in the brain [46,47]. In this study,
we found that LPS systemic injection (5 mg/kg) markedly
up-regulated the level of Cat H expression predominantly
in activated microglia. A low dose of LPS (0.1 mg/kg, i.p.)
injection in our pre-experiments evoked neuroinflamma-
tion but failed to induce brain Cat H expression.
Our in vitro study further demonstrated that the pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ) have
an inducible effect on release and enzymatic activity of
Cat H in microglia. The gradient doses of proinflamma-
tory agents for stimulating microglia were derived from
literatures concerned [64,65]. It is notable that Cat H
level in the culture medium of primary microglia was
lower than BV2 cells following inflammatory stimuli.
This difference may be associated with biological charac-
teristics of two types of cells. Additionally, the frequency
of propagation of BV2 cells may contribute to the differ-
ent biological characteristics from primary microglia.
Figure 5 Cat H induced neuronal death in vitro. The effect of Cat H in various concentrations on Neuro2a cell survival was measured by flow
cytometry (A-D); TUNEL positive staining exhibited the morphological changes of Neuro2a cells after addition of Cat H (E-F). Data were expressed as
mean + SEM from three independent experiments. *, #: P < 0.05 vs control.
Fan et al. Journal of Neuroinflammation  (2015) 12:54 Page 9 of 12On the other hand, active Cat H induced microglial acti-
vation characterized by the release of NO and various pro-
inflammatory cytokines. More importantly, active Cat H
was toxic to neurons and induced neuronal death. These
findings lead us to a hypothesis that the functional link of
Cat H with microglia activation might involve a self-
sustaining amplifying circle, contributing to the initiation
and maintenance of microglia-driven chronic inflamma-
tion (Figure 6). To the best of our knowledge, this is the
first report to reveal the regional expression and cellular
localization of Cat H in the brain and highlight its poten-
tially functional role in neuroinflammation.
Several clinical reports showed that Cat H was in-
volved in pathological processes of many peripheral in-
flammatory diseases, in which the levels of Cat H were
dramatically increased in the secretory compartment of
cells or in the serum of patients [42,66]. These findings
indicate that Cat H can be secreted via the secretory
lysosome system during pathological processes. The se-
cretive property of Cat H would allow access to the
extracellular environment and exert the extracellular ac-
tion [67].
Considering the antibody for Cat H, immunoassay
used in our study is specific for mature single-chain
form of Cat H (28 kDa); therefore, we rationally specu-
late that Cat H protein detected in media of microgliafollowing the inflammatory activation was in mature
form, not in inactive form. The results confirm the pre-
vious reports that extracellularly secreted Cat H is
mainly in mature form, unlike cathepsins B, K, and S
which were mostly zymogens [32,42].
Mature Cat H has unique aminopeptidase activity,
which is distinguished from other cysteine proteases,
such as cathepsins B and L [68]. The crystal structure of
mature Cat H determines greatly its limited endopeptid-
ase activity on synthetic and natural substrates [35,39].
Aminopeptidases are exopeptidases that catalyze the hy-
drolysis of amino acid residues from the N-terminus of
peptides or proteins. Disturbance of the normal balance
of aminopeptidase activity may lead to inflammatory
events and tumor progression [36-38]. As demonstrated
in our enzyme assay, the aminopeptidase activity of Cat
H is increased in the media of microglia following in-
flammatory stimulation. It is known that the cathepsin
activity is regulated in many ways, that is, gene expres-
sion, zymogen activation, cellular environment, and
presence or absence of inhibitors [54]. In this study, the
increase of Cat H enzymatic activity could be due, in
part, to the expression level of the fully processed ma-
ture Cat H form. However, it is hard to explain the dif-
ferences between protein and activity of Cat H in
primary microglia. We speculate that Cat H activity may
Figure 6 The function link of Cat H with microglia activation inducing neuronal apoptosis. Inflammatory cytokines induced Cat H release
from microglia and enhanced its activity. Also, Cat H induced microglial activation characterized by the release of inflammatory cytokines. Cat H,
alone or in combination of inflammatory cytokines, contributes to neuronal apoptosis.
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tein content. The mechanisms of regulation of Cat H ac-
tivity need further study.
To date, the mechanisms of overproduced Cat H in-
volved in immune responses remain unclear. Perez et al.
found that rats injected with Cat H intracutaneously had
acute dermal inflammation characterized by the local ac-
cumulation of PMN under the action of chemotactic fac-
tors [40]. In our in vitro study, recombinant active Cat
H protein exerted an inducible impact on the release of
IL-1β and IFN-γ in microglia, which could be prevented
by specific neutralizing antibody obviously. It implies
strongly that Cat H could participate in and even aggra-
vate inflammatory responses through inducing the re-
lease of inflammatory factors.
In addition, several studies have identified that Cat H
primarily participates in pathological apoptosis, for in-
stance, Nitatori et al. reported that Cat H was involved
in apoptosis of CA1 pyramidal neurons after brief ische-
mia [69]. Our in vitro study demonstrated that recom-
binant active Cat H caused significant neuronal death
when added directly to the neuroblastoma cell line Neu-
ro2a, indicating that Cat H exerted cytotoxic effects on
neurons. The mechanisms of Cat H mediating neuronal
death is thought to be associated with cathepsin C.
Under certain proinflammatory conditions, Cat H co-
operating with cathepsin C can converse pro-granzyme
B (proGrB) into granzyme B (GrB) in immune cells in-
cluding cytotoxic lymphocytes (CTLs), natural killer
(NK) cells, activated macrophages, and neutrophils.
Once released, GrB can cleave extracellular matrix
resulting in local proteolysis and tissue damage orfurther delivered into target cells by pore-forming protein
perforin to induce cell death [70,71]. In this study, we can-
not ascertain the mechanisms underlying Cat H-mediated
neuronal death. We speculate that secreted Cat H may
function as a ligand rather than a catabolic enzyme, dir-
ectly binding to as yet unidentified specific receptors on
the surfaces of neurons, which is responsible for triggering
intracellular death-related signaling pathways.
Conclusions
In summary, in the present study, we investigated the tem-
poral and spatial expression patterns of Cat H in the brain
in LPS-evoked neuroinflammation. We found the promin-
ent up-regulation of Cat H expression in brain microglia
after LPS injection. In vitro study further confirmed that
proinflammatory cytokines could induce release of Cat H
in microglia, which could exert a profound and detrimental
impact on microglial activation and neuronal survival. Elu-
cidation of the precise mechanism underlying the neuro-
toxicity of microglial Cat H may provide insights into how
microglia influences neuronal functions and status in neu-
roinflammation. In addition, control of inflammatory re-
sponse and inhibition of the Cat H level in the brain would
be important for prevention and treatment of neurodegen-
erative diseases that are associated with excessive microglial
activation and subsequent neurotoxic inflammation.
Additional files
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